The official Drugs@FDA dataset lists original submission 1 for ANDA 208086 with status AP dated 2020-12-28, and names glucagon among the application record's active ingredients.
The Federal Register published notice 2020-27760, attributed to FDA and its parent HHS department, on 2020-12-17. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212081 with status AP dated 2020-12-16, and names icatibant acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 1 for the reviewed Setmelanotide label family with a published date of 2020-12-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 15 for the reviewed Lixisenatide label family with a published date of 2020-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2020-26133, attributed to FDA and its parent HHS department, on 2020-11-25. Its official title is “Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 213793 with status AP dated 2020-11-25, and names setmelanotide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 8 for the reviewed Plecanatide label family with a published date of 2020-11-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 7 for the reviewed Abaloparatide label family with a published date of 2020-11-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The Federal Register published notice 2020-23300, attributed to FDA and its parent HHS department, on 2020-10-21. Its official title is “Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213054 with status AP dated 2020-10-05, and names icatibant acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 23 for the reviewed Linaclotide label family with a published date of 2020-10-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210223 with status AP dated 2020-09-17, and names desmopressin acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 36 for the reviewed Dulaglutide label family with a published date of 2020-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211501 with status AP dated 2020-09-02, and names icatibant acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211403 with status AP dated 2020-08-31, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213425 with status AP dated 2020-08-20, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2020-18240, attributed to FDA and its parent HHS department, on 2020-08-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 212593 with status AP dated 2020-08-03, and names vasopressin among the application record's active ingredients.
The Federal Register published notice 2020-16649, attributed to FDA and its parent HHS department, on 2020-07-31. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
DailyMed lists Structured Product Labeling version 14 for the reviewed Lixisenatide label family with a published date of 2020-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212446 with status AP dated 2020-07-13, and names icatibant acetate among the application record's active ingredients.
The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 208232 with status AP dated 2020-06-26, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208317 with status AP dated 2020-06-18, and names icatibant acetate among the application record's active ingredients.
The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.
DailyMed lists Structured Product Labeling version 7 for the reviewed Plecanatide label family with a published date of 2020-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 6 for the reviewed Plecanatide label family with a published date of 2020-04-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Afamelanotide label family with a published date of 2020-04-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Lixisenatide label family with a published date of 2020-03-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Afamelanotide label family with a published date of 2020-03-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 207864 with status AP dated 2020-03-20, and names eptifibatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211021 with status AP dated 2020-03-09, and names icatibant acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 35 for the reviewed Dulaglutide label family with a published date of 2020-03-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.
DailyMed lists Structured Product Labeling version 5 for the reviewed Plecanatide label family with a published date of 2020-02-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210218 with status AP dated 2020-02-14, and names desmopressin acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 12 for the reviewed Lixisenatide label family with a published date of 2020-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 213182 with status AP dated 2020-01-16, and names semaglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 34 for the reviewed Dulaglutide label family with a published date of 2020-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.